# Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

> **NCT03941236** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Zealand Pharma** · enrollment: 42 (actual)

## Conditions studied

- Congenital Hyperinsulinism

## Interventions

- **DRUG:** dasiglucagon

## Key facts

- **NCT ID:** NCT03941236
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-02
- **Primary completion:** 2025-01-28
- **Final completion:** 2026-12-31
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03941236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03941236, "Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03941236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*